Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery

Blood Adv. 2023 Jan 24;7(2):224-226. doi: 10.1182/bloodadvances.2021006696.
No abstract available

MeSH terms

  • Anticoagulants / therapeutic use
  • Bariatric Surgery* / adverse effects
  • Humans
  • Rivaroxaban
  • Venous Thromboembolism* / drug therapy
  • Venous Thromboembolism* / etiology

Substances

  • Anticoagulants
  • Rivaroxaban